Cytokine profiles of multiple myeloma and waldenström macroglobulinemia;Cytokinové profily mnohočetného myelomu a Waldenströmovy makroglobulinemie

Klinicka Onkologie

Volumn 27, Issue 1, 2014, Pages 18-23

  Sedlarikova L ^a,b   Sadilkova K ^a   Kubiczkova L ^a,b   Hajek R ^a,b   Sevcikova, Sabina ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Bone marrow microenvironment; Cytokines; Multiple myeloma; Waldenstr m macroglobulinemia

Indexed keywords

CYTOKINE;

CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; MULTIPLE MYELOMA; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; TUMOR CELL; WALDENSTROEM MACROGLOBULINEMIA; BIOSYNTHESIS; BONE MARROW; CELL DIVISION; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

BONE MARROW; CELL DIVISION; CELL SURVIVAL; CYTOKINES; HUMANS; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WALDENSTROM MACROGLOBULINEMIA;

EID: 84894426761     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko201418     Document Type: Review

References (66)

1. Hájek R, Krejčí M, Pour L et al. Multiple myeloma. Klin Onkol 2011; 24 (Suppl 1): S10-S13.
2. Adam Z, Smardová J, Scudla V. Waldenströmova makroglobulinemie: klinické projevy a diferencialní diagnostika a prognóza nemoci. Vnitr Lek 2007; 53(12): 1325-1337.
3. Balakumaran A, Robey PG, Fedarko N et al. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn 2010; 10(4): 465-480.
4. Haas HS, Schauenstein K. Neuroimmunomodulation via limbic structures - the neuroanatomy of psychoimmunology. Prog Neurobiol 1997; 51(2): 195-222. (Pubitemid 27112410)
5. Negus RP, Balkwill FR. Cytokines in tumour growth, migration and metastasis. World J Urol 1996; 14(3): 157-165. (Pubitemid 126775157)
6. Naugler WE, Karin M. The wolf in sheep's clothing. the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14(3): 109-119.
7. Mitsiades CS, Mitsiades N, Munshi NC et al. Focus on multiple myeloma. Cancer Cell 2004, 6(5): 439-444. (Pubitemid 39469979)
8. Chng, WJ, Schop RF, Price-Troska T et al. Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 2006; 108(8): 2755-2763.
9. Uchiyama H, Barut BA, Mohrbacher AF et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82(12): 3712-3720. (Pubitemid 24006055)
10. Dankbar B, Padró T, Leo R et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95(8): 2630-2636. (Pubitemid 30210543)
11. Jourdan M, Mahtouk K, Veyrune JL et al. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw 2005; 16(1): 57-64. (Pubitemid 40478077)
12. Abildgaard N, Glerup H, Rungby J et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000; 64(2): 121.
13. Hatzimichael EC, Christou L, Bai M et al. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia. Eur J Haematol 2001; 66(1): 1-6. (Pubitemid 32099402)
14. Blanchard F, Duplomb L, Baud'huin M et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. Cytokine Growth Factor Rev 2009; 20(1): 19-28.
15. Elsawa SF, Novak AJ, Ziesmer SC et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011; 118(20): 5540-5549.
16. Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 2007; 5(3): 98-104. (Pubitemid 47577320)
17. Corso A, Dovio A, Rusconi C et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia 2004; 18(9): 1555-1557. (Pubitemid 39264084)
18. Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102(3): 1064-1069. (Pubitemid 36917805)
19. Marcelli C, Chappard D, Rossi JF et al. Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer 1988; 62(6): 1163-1170.
20. Terpos E, Anagnostopoulos A, Kastritis E et al. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in Waldenström macroglobulinaemia. Br J Haematol 2006; 133(3): 301-304.
21. Terpos E,Tasidou A, Eleftherakis-Papaiakovou E et al. Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. Clin Lymphoma Myeloma Leuk 2011; 11(1): 115-117.
22. Miñano FJ, Sancibrian M, Vizcaino M at al. Macrophage inflammatory protein-1: unique action on the hypothalamus to evoke fever. Brain Res Bull 1990; 24(6): 849-852. (Pubitemid 20207207)
23. Kukita T, Nomiyama H, Ohmoto Y et al. Macrophage inflammatory protein-1α (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest 1997; 76(3): 399-406. (Pubitemid 27157347)
24. Uneda S, Hata H, Matsuno F et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120(1): 53-55. (Pubitemid 36056908)
25. Michigami T, Shimizu N, Williams PJ et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96(5): 1953-1960.
26. Vallet S, Pozzi S, Patel K et al. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011; 25(7): 1174-1181. doi: 10.1038/leu.2011.43
27. Lentzsch S, Gries M, Janz M et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101(9): 3568-3573. (Pubitemid 36857943)
28. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999,13(1): 9-22. (Pubitemid 29038270)
29. Okada F, Rak JW, Croix BS et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras upregulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998; 95(7): 3609-3614.
30. Kumar S, Witzig TE, Timm M et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17(10): 2025-2031. (Pubitemid 37322133)
31. Rajkumar SV, Mesa RA, Fonseca R et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8(7): 2210-2216. (Pubitemid 34753592)
32. Podar K, Tai YT, Davies FE et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98(2): 428-435.
33. Marković O, Marisavljević D, Čemerikić V et al. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol 2008; 25(4): 451-457.
34. Podar K, Anderson K. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implication. Blood 2005; 105(4): 1383-1395. (Pubitemid 40223651)
35. Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly 51 enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473(2): 161-164. (Pubitemid 30254282)
36. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity Br J Haematol 2007; 137(6): 560-568. (Pubitemid 46817338)
37. Kumar S, Witzig TE, Timm M et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory aktivity with disease progression. Blood 2004; 104(4): 1159-1165. (Pubitemid 39038038)
38. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin like growth factor I and its structural homology, with proinsulin. J Biol Chem 1978; 253(8): 2769-2776. (Pubitemid 8326483)
39. Menu E, van Valckenborgh E, van Camp B et al. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115(2): 49-57.
40. Qiang YW, Yao L, Tosato G et al. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004; 103(1): 301-308. (Pubitemid 38029952)
41. Standal T, Borset M, Lenhoff S et al. Serum insulin-like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002; 100(12): 3925-3929. (Pubitemid 35396856)
42. Leleu X, Jia X, Runnels J et al.The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110(13): 4417-4426. (Pubitemid 351377808)
43. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189(11): 1747-1756. (Pubitemid 29272691)
44. Mackay F, Schneider P, Rennert P et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231-264. (Pubitemid 37174532)
45. Xu G, Shen XJ, Pu J et al. BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells. Cytokine 2012; 60(2): 505-513.
46. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404(6781): 995-999. (Pubitemid 30243593)
47. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293(5537): 2108-2111. (Pubitemid 32848062)
48. Hahne M, Kataoka T, Schröter et al. APRIL, a new ligand of the tumor necrosis factor family, stimulans tumor cell growth. J Exp Med 1998; 188(6): 1185-1190. (Pubitemid 28443341)
49. Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103(2): 689-694. (Pubitemid 38140105)
50. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2(12): 927-937. (Pubitemid 37328894)
51. Elsawa SF, Novak AJ, Grote DM et al B-lymphocyte stimulator (BlyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood 2006; 107: 2882-2888.
52. Cohen S, Shachar I. Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells. Cytokine 2012; 60(1): 13-22. doi: 10.1016/j.cyto.2012.06.019.
53. Derksen PW, de Gorter DJ, Meijer HP et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17(4): 764-774. (Pubitemid 36519374)
54. Mahtouk K, Tjin EP, Spaargaren M et al. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 2010; 1806(2): 208-219. doi: 10.1016/j.bbcan 2010.07.006.
55. Hov H, Holt RU, Roø TB et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004; 10(19): 6686-6694. (Pubitemid 39346566)
56. Du W, Hattori Y, Yamada T et al. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007; 109(7): 3042-3049. (Pubitemid 46482105)
57. Seidel C, Boørset M, Turesson I et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91(3): 806-812. (Pubitemid 28078282)
58. Alexandrakis MG, Passam FH, Sfiridaki A et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003; 72(4): 229-233. (Pubitemid 36383972)
59. Hov H, Tian E, Holien T et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol 2009; 82(4): 277-287. doi: 10.1111/j.1600-0609.2009.01212.
60. Standal T, Abildgaard N, Fagerli UM et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109(7): 3024-3030. (Pubitemid 46482103)
61. Holt RU, Baykov V, Rø TB et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 2005; 90(4): 479-488. (Pubitemid 40592890)
62. Minarik J, Pika T, Bacovsky J et al. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance. ScientificWorldJournal 2012; 2012: 356128. doi: 10.1100/2012/356128.
63. Scudla V, Budíková M, Petrová P et al. Analýza sérových hladin vybraných bio logických ukazatelů monoklonální gamapatie nejistého významu a mnohočetného myelomu. Klin Onkol 2010; 23(3): 171-181.
64. Pour L, Svachova H, Adam Z et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2010; 89(4): 385-389. doi: 10.1007/s00277-009-0834-3.
65. Pour L, Svachova H, Adam Z et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010; 57(1): 29-34.
66. Pour L, Svachova H, Adam Z et al. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 2010; 84(4): 332-336. doi: 10.1111/j.1600-0609.200901396.x.